- Motley Fool•20 hours ago
If you're not buying Bristol-Myers because of last year's Opdivo trial failure, you ought to reconsider.
- Investor's Business Daily•2 days ago
Bristol-Myers Squibb's Merck-rivaling immuno-oncology drug, Opdivo, grew 60% in the first quarter, helping the drugmaker to smash Wall Street's expectations.
- Reuters•2 days ago
Bristol-Myers Squibb Co on Thursday reported higher-than-expected quarterly earnings, helped by increased sales of cancer drugs Opdivo and Yervoy and blood thinner Eliquis. The U.S. drugmaker, which has faced increasing competition for blockbuster Opdivo as well as pressure from activist investors, also raised its full-year earnings outlook, reversing a cut it made in January. Opdivo sales jumped 60 percent in the first quarter, while Eliquis gained 50 percent and Yervoy rose 25 percent.
MRK : Summary for Merck & Company, Inc. (new) - Yahoo Finance
Merck & Co., Inc. (MRK)
NYSE - NYSE Delayed Price. Currency in USD
Add to watchlist
|Bid||62.20 x 300|
|Ask||62.42 x 500|
|Day's Range||62.14 - 62.65|
|52 Week Range||53.06 - 66.80|
Trade prices are not sourced from all markets
|PE Ratio (TTM)||44.21|
|Dividend & Yield||1.88 (3.00%)|
|1y Target Est||N/A|